Nature’s Toolbox (NTx) – a life sciences company building next-generation platforms to manufacture RNA and protein – recently announced that it has raised $47.5M in Series B financing. Led by RA Capital Management, the funding will fuel the advancement of the company’s biomanufacturing platforms NTxscribe and NTxpress. And the acceleration of these technology foundations will enable the distribution of manufacturing capabilities globally, ultimately providing solutions to prepare for future pandemic events, personalized medicine therapy, and increased access to critical vaccines and medicines.
The historic challenges with conventional manufacturing processes and supply chain stability have slowed progress and increased costs for the development of critical vaccines and biologics. And the NTxscribe platform is a cell-free, true continuous flow manufacturing system that addresses these challenges by delivering scalable RNA materials in a small footprint.
NTxscribe is now being deployed in BioPharma research and development to help expedite mRNA therapeutic development. And it is also the technology being evaluated in the first Vaccines-on-Demand contract awarded by BARDA DRIVe for pandemic preparedness. NTxpress is a fully recombinant cell-free expression system that develops proteins while minimizing unwanted cellular metabolism.
This approach is expected to transform compound production with broad application in numerous markets including therapeutics, materials, chemicals, and environmental. And the Series B funding will accelerate NTx’s development of the NTxscribe and NTxpress platforms into commercially available solutions including the manufacturing of biomaterials for producing mRNA and proteins.
KEY QUOTES:
“This financing will help us work toward our mission of delivering innovative biomanufacturing solutions designed to manufacture therapeutics in a more rapid, accessible, and sustainable way. This was also the largest Series B round raised by a New Mexico life sciences company in recent history. We are thrilled to have RA Capital Management lead the round. This major commitment and the addition of Peter Kolchinsky, Ph.D. to our Board of Directors will accelerate NTx’s technology development and commercial penetration with leading biopharma, healthcare, and government entities.”
— Jamie Coffin, Ph.D., CEO of NTx
“Having low cost of goods is critical to unlocking the full societal value of any novel modality, and NTx has cracked the code for dramatically reducing the cost and scalability of producing mRNA. NTx will help the entire field of mRNA, spanning scores of companies and hundreds of programs, to reach their global potential.”
— Peter Kolchinsky, Ph.D., Managing Partner at RA Capital Management
